Leerink maintains Outperform on Arcturus Therapeutics; sets $19 target
Leerink Partners reiterated an Outperform rating on Arcturus Therapeutics and kept a $19.00 price target.
Story updates
12:38:22 PM UTC
SquawkNews
Ratings actions from Benzinga: GMT) Arcturus Therapeutics Price Target Raised to $19.00/Share From $13.00 by Leerink PartnersRatings actions from Benzinga